A new $800 million biotech manufacturing facility will be built in Melbourne to provide vaccine production and protect the nation against future pandemic threats.
Seqirus, a subsidiary of Victorian-based global biopharmaceutical leader CSL, will invest more than $800 million to build the facility at the Melbourne Airport Business Park, with operations expected to start in 2026.
The project secures more than 1000 jobs, generate export contracts and provide continuing support for hundreds of organisations estimated to be worth $300 million to the local supply chain.
“The Victorian Government is proud to have provided significant support to secure this vital facility in Melbourne, which will support hundreds of jobs and many more in the supply chain,” Industry Support and Recovery Minister Martin Pakula said.
“This investment is a significant coup for Victoria. It positions the state as a global leader in cell-based influenza vaccine production and further boosts our capabilities in R&D, commercialisation and advanced manufacturing.”
- Mechatronics to drive the engineering jobs of the future
- Stockland acquires 131 hectares of land in Melbourne’s south east
- Melbourne suburbs get $25M infrastructure boost
The facility is expected to be the only cell-based influenza vaccine manufacturing facility in the southern hemisphere. It will also produce other life-saving products for the Australian market such as the world’s only Q-Fever vaccine and anti-venom for local snakes, spiders and marine creatures.
An agreement between the Federal Government and Seqirus has secured the supply of these products and influenza pandemic protection for Australia over the next 10 years.
The new facility will produce seasonal influenza vaccines for use globally and have the capacity to rapidly scale up vaccine production in response to any future influenza pandemic.
“For more than 100 years CSL has been on the front line of the fight against influenza and we are excited to work with Victoria’s world-class talent to deliver the next generation of influenza vaccine technology to Australia,” Seqirus General Manager Stephen Marlow said.